Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a growth of 13.66% [2] - The net cash flow from operating activities was 714 million CNY, an increase of 35.39% [2] - The weighted average return on equity was 4.86%, up by 0.68 percentage points year-on-year [2] - The company held cash and cash equivalents of 11.062 billion CNY, with total assets amounting to 54.253 billion CNY [2] R&D Advantages - Strong R&D capabilities with a rich reserve of leading talents, established a joint research center with Peking University [3][4] - Integrated R&D resources across multiple cities, enhancing collaboration with top research institutions [4] - Proactive strategic layout in nuclear medicine, focusing on unmet clinical needs in oncology and immunology [4] - Financial strength to support long-term R&D investments in nuclear medicine [4] Traditional Chinese Medicine (TCM) Supply Chain Development - The company is taking the lead in the TCM supply chain in Yunnan, focusing on seed industry, planting, processing, marketing, and branding [5][6] - Established a specialized company for TCM seed industry, with 4,593 acres of GAP varieties reported in 2024 [6] - Significant growth in production, with a 180% increase in fresh processing and 182% in food and health products [6] - Launched the 'Smart Cloud Medicine' platform, facilitating over 100 million CNY in transactions [6] - Participated in the revision of standards for TCM in the 2025 edition of the Chinese Pharmacopoeia [6] Pharmaceutical Business Growth - The pharmaceutical division focused on comprehensive pain management, enhancing brand recognition in the field [7][8] - Continued clinical research on core products, expanding applications in various medical scenarios [8] - Successful marketing initiatives aimed at younger demographics, leading to increased sales [8] - Established efficient online business processes to enhance operational effectiveness [8]

Group 1: Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a 13.66% increase compared to the previous year [2] - The net cash flow from operating activities was 714 million CNY, showing a significant growth of 35.39% [2] - The weighted average return on equity was 4.86%, an increase of 0.68 percentage points year-on-year [2] - The company had a cash balance of 11.062 billion CNY and total assets of 54.253 billion CNY [2] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment focused on pain management, enhancing brand recognition and product ecosystem [4] - Clinical research in areas such as diabetic foot and skeletal pain showed steady progress, expanding product application scenarios [4] - Successful marketing initiatives, including the 'Walk and Play' campaign, contributed to brand youthfulness and increased product penetration [4] - The company established an efficient operational system to enhance production and marketing effectiveness [4] Group 3: Traditional Chinese Medicine (TCM) Supply Chain Development - The company is committed to leading the TCM supply chain in Yunnan, focusing on seed industry, cultivation, processing, and branding [6] - A new company was established for TCM seed industry, providing control over genetic resources [6] - The processing platform saw a production increase of 180% for medicinal materials and 182% for health products [6] - The 'Smart Cloud Medicine' platform was launched, facilitating transactions exceeding 100 million CNY [6] - The company participated in the revision of standards for TCM products, leading in the development of processing standards [6] Group 4: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with positive stability and safety results reported [8] - The company’s subsidiary received approval for clinical trials of INR102, an innovative radioactive treatment for prostate cancer [8]

Group 1: Pharmaceutical Business Performance - In 2024, the pharmaceutical segment achieved a revenue of 6.924 billion CNY, a year-on-year increase of 11.8% [2] - The sales revenue of Yunnan Baiyao aerosol exceeded 2.1 billion CNY, growing over 26% [2] - The sales of other traditional Chinese medicine products, such as Pudilan's anti-inflammatory tablets, reached nearly 200 million CNY, with a significant growth of over 22% [4] Group 2: Traditional Chinese Medicine Supply Chain Development - Yunnan Baiyao is committed to being the "chain leader" in the traditional Chinese medicine supply chain in Yunnan Province [3] - The company established a specialized traditional Chinese medicine seed company to control genetic resources [4] - The "Shuzhi Cloud Medicine" platform was launched, facilitating transactions exceeding 100 million CNY [4] Group 3: Oral Care Product Sales and Market Strategy - The health product segment generated 6.526 billion CNY in revenue, with a year-on-year growth of 1.6% [5] - Yunnan Baiyao toothpaste maintained the top market share in the domestic oral care sector [5] - The company is enhancing its channel strategy by optimizing traditional offline channels and exploring new retail formats [5] Group 4: Q1 2025 Financial Performance - In Q1 2025, the company reported a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [7] - The net profit attributable to shareholders was 1.935 billion CNY, growing by 13.67% [7] - The cash flow from operating activities reached 714 million CNY, up 35.39% year-on-year [7] Group 5: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024 and completed its I/IIa phase clinical summary report in November [8] - The company’s subsidiary received approval for the clinical trial of INR102, aimed at treating metastatic castration-resistant prostate cancer [9]

Group 1: Pharmaceutical Business Direction - The pharmaceutical business group aims to be a model for the inheritance and innovative development of traditional Chinese medicine, focusing on optimizing existing products and providing comprehensive operational plans for major disease treatment areas such as cardiovascular, respiratory, and pediatrics [2] - The group will continue secondary development of existing products and selectively extend external projects to strengthen the pharmaceutical system [2] Group 2: Traditional Chinese Medicine Industry Chain Development - The company is committed to building a world-class modern traditional Chinese medicine industry in Yunnan, focusing on seed industry, planting, processing, marketing, and branding [3] - A specialized company for traditional Chinese medicine seed industry has been established, with 7 GAP varieties applied for in 2024 covering 4,593 acres [4] - The production of Qi Xue Kang oral liquid won the title of Yunnan Province's manufacturing single champion, with a 180% increase in production during the reporting period [4] - The "Shuzhi Yun Yao" platform was launched, achieving over 100 million yuan in transaction volume, enhancing the standardization of traditional agricultural products [4] Group 3: Yao Yuan Qing Product Performance - In 2024, Yao Yuan Qing hair care products achieved sales revenue of 422 million yuan, a year-on-year increase of 30.3% [5] - The brand has gained significant market penetration, ranking first in Tmall's domestic anti-hair loss shampoo category during major sales events [6] Group 4: Q1 2025 Financial Performance - In Q1 2025, the company reported revenue of 10.841 billion yuan, a year-on-year increase of 0.62% [7] - Net profit attributable to shareholders was 1.935 billion yuan, up 13.67% year-on-year, with a basic earnings per share of 1.08 yuan [7] - The net cash flow from operating activities increased by 35.39% to 714 million yuan [7] Group 5: Health Product Channel Development - The company has a well-established national sales team for health products, maintaining a leading market share in toothpaste [8] - Continuous optimization of the entire channel has strengthened traditional offline advantages while exploring new retail formats [9]

Group 1: Investment and Growth Strategy - The company plans to optimize its industrial portfolio through both "internal" and "external" collaborative development, focusing on strategic mergers and partnerships to overcome growth bottlenecks and achieve sustainable development [2][3]. Group 2: Pharmaceutical Business Performance - In 2024, the pharmaceutical segment achieved significant growth by positioning itself as the "leading brand in comprehensive pain management," enhancing product visibility and ecosystem through clinical research and marketing strategies [4][5]. - The pharmaceutical group reported steady progress in clinical studies for various products, including those targeting diabetic foot and bone pain, contributing to broader application scenarios [4]. Group 3: Traditional Chinese Medicine (TCM) Supply Chain Development - The company is committed to developing a world-class modern TCM industry, with initiatives in seed cultivation, planting, processing, and branding, including the establishment of a specialized seed company [6][7]. - In 2024, the company reported a 180% increase in the production of fresh medicinal materials and a 182% increase in food and health product output, supporting high-quality development [6]. Group 4: Health Products Performance - The health product segment, particularly the Yangyuanqing hair care line, achieved sales revenue of 422 million yuan in 2024, marking a 30.3% year-on-year growth [8]. Group 5: Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with promising results indicating excellent stability and safety [9][11]. Group 6: Health Product Channel Development - The company maintains a comprehensive national sales team for health products, with a leading market share in oral care products, and is optimizing both traditional and emerging sales channels [12]. Group 7: Digital Transformation Initiatives - The company is implementing a digital development plan (2022-2026) that leverages AI and data to enhance all aspects of the supply chain, aiming for a smart and green transformation in the TCM industry [13][14]. Group 8: Provincial Pharmaceutical Company Performance - The provincial pharmaceutical company achieved a main business revenue of 24.607 billion yuan in 2024, with a 0.48% year-on-year growth, and significant increases in non-pharmaceutical business sales [15][16].

Financial Performance - In 2024, the company achieved operating revenue of 40.033 billion CNY, a year-on-year increase of 2.36% [2] - Net profit attributable to shareholders reached 4.749 billion CNY, up 16.02% from 4.094 billion CNY in the previous year [2] - Non-recurring net profit attributable to shareholders was 4.523 billion CNY, a 20.18% increase from 3.764 billion CNY [2] - Operating cash flow net amount was 4.297 billion CNY, growing by 22.68% [3] - The weighted average return on net assets was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share rose to 2.66 CNY, a 16.16% increase [3] Business Structure and Efficiency - Industrial revenue accounted for 36.14% of total operating revenue, with an industrial revenue growth rate of 5.30% [3] - Industrial gross margin improved to 65.93%, up 1.69 percentage points [3] - Sales expenses decreased by 2.26% year-on-year, while management expenses fell by 1.98% [3] Pharmaceutical Business Performance - The pharmaceutical business group reported main business revenue of 6.924 billion CNY, a year-on-year increase of 11.8% [4] - Sales revenue of Yunnan Baiyao aerosol exceeded 2.1 billion CNY, growing over 26% [4] - Other traditional Chinese medicine products also saw significant growth, with Pudilan's sales nearing 200 million CNY, up over 22% [4] Traditional Chinese Medicine Industry Development - The company is leading the development of Yunnan's traditional Chinese medicine industry, focusing on seed industry, planting, processing, and branding [5][6] - Established Yunnan Baiyao Group Seed Technology Co., Ltd. for seed quality control [6] - The processing platform in Lijiang achieved a production increase of 180% [6] - The "Smart Cloud Medicine" platform launched, facilitating over 100 million CNY in transactions [6] Provincial Pharmaceutical Company Performance - The provincial pharmaceutical company achieved main business revenue of 24.607 billion CNY, a year-on-year increase of 0.48% [7] - Non-drug business sectors like medical devices and special medical foods saw a sales increase of 14% [8] - The OTC sector experienced a sales growth of 18%, while new specialty drug pharmacies grew by 29% [8]

Group 1: Future Development Plans - The pharmaceutical business group aims to be a model for the inheritance and innovative development of traditional Chinese medicine, focusing on major disease treatment areas such as cardiovascular, respiratory, and pediatrics [2] - The strategy includes optimizing the existing product system and providing comprehensive operational plans to achieve strategic growth [2] Group 2: Health Products Business Performance - In 2024, the health products business achieved revenue of CNY 6.526 billion, a year-on-year increase of 1.6%, and profit of CNY 2.191 billion, up 8.36% [3] - The oral care segment maintained the top market share in China, while the anti-hair loss product line saw a revenue increase of 30.3% [4] Group 3: Traditional Chinese Medicine Supply Chain Development - The company is committed to developing Yunnan's traditional Chinese medicine industry, establishing a specialized seed company and applying for GAP certification for 7 varieties covering 4,593 acres [5] - The production of medicinal materials increased significantly, with a 180% rise in output and a 182% increase in food and health product production [6] Group 4: Dividend Distribution - The company plans to distribute a cash dividend of CNY 11.85 per 10 shares, with a total cash dividend amounting to CNY 4.278 billion, representing 90.09% of the net profit attributable to shareholders for 2024 [7]